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ABSTRACT
As the cost of health care continues to rise and insurance reimbursements have
decreased, organizations have to find avenues to cut costs and increase profits. A goal of
this project is to help prepare anesthesia providers with the best evidence-based
knowledge about sugammadex and neostigmine and allow providers to make a sound,
cost-efficient decision when choosing a reversal method. A needs assessment was
conducted with the chief certified registered nurse anesthetist (CRNA) at a north delta
Mississippi facility. The needs assessment demonstrated that cost was the main concern
and reason for choosing neostigmine over sugammadex. Further, providers at the chosen
hospital also wanted to know whether the benefits of sugammadex outweighed the cost of
the medication.
A thorough literature review and detailed cost analysis indicated that
sugammadex is a superior reversal agent for reversing the paralytic effects of rocuronium
and could create a cost-effective surgical care model if implemented fully into clinical
practice. The cost-benefit analysis of neostigmine versus sugammadex demonstrated that
the purchasing price of sugammadex was more expensive than the cost of neostigmine,
but a thorough literature review and detailed cost analysis indicated that sugammadex
could potentially have a cost savings of $345,640 to $997,064 over a 6-month period by
increasing the rate of discharge from the operating room. Sugammadex has a purchasing
cost of $70.72, and if this reversal technique was used for each of the 800 abdominal
surgical cases over the 6-month period, the overall purchasing cost would be $48,360.
Implementing sugammadex into clinical practice could have a potential cost
savings of $345,640 at minimum over a 6-month period after the purchasing cost of
ii

sugammadex is considered and will drastically improve patient outcomes by preventing
residual muscle paralysis from incomplete reversal of paralysis. An evidence-based
literature review and a detailed cost analysis demonstrated that sugammadex is far
superior in reversing the effects of rocuronium and can allow operating rooms to save a
tremendous amount of money by improving operating room discharge times, which
would offset the purchasing cost of sugammadex and create an efficient surgical care
model.
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CHAPTER I - INTRODUCTION
With the rising cost of health care and limited reimbursement from insurance
companies, organizations are continually trying to find new avenues to decrease costs and
improve profits. The healthcare reform has forced anesthesia providers to critique their
anesthetic plan to ensure cost savings and make providers aware of anesthetic costs, such
as medicines (Zhou, 2016). In anesthesia, multiple drug options are available to cause the
same effect, such as reversals for neuromuscular blocking agents.
In anesthesia, several options exist for neuromuscular blockade reversal. The two
most commonly used are neostigmine and sugammadex. Neostigmine, an
anticholinesterase, is currently the most widely used drug for neuromuscular blockade
reversal. While sugammadex is a newer option that is being implemented into practice to
reverse the effects of steroidal neuromuscular blockers such as rocuronium. The cost and
benefits of each medication were the focus of this investigation to determine the most
evidence-based proven reversal method and its associated cost. Providers’ knowledge and
preference were also investigated to further evaluate each medication and why a provider
chooses one reversal over another.
Problem Description
Are the benefits of sugammadex worth the expense when reversing steroidal
neuromuscular blockers when compared to neostigmine? The purpose of this project was
to investigate the cost and benefit comparison of sugammadex versus neostigmine. A
cost-benefit analysis was performed to compare the medications.
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Purpose and Context
The cost and benefits of each medication were the focus of this investigation to
determine the most evidence-based proven reversal method and its associated cost
between neostigmine and sugammadex. Provider preference were investigated by
administering a survey to an expert group of providers to help answer whether
sugammadex was worth the associated expense. Finally, sugammadex and neostigmine
were compared to each other to discover which reversal technique provides improved
patient outcomes.
Purpose of the Project
The purpose of this project was to investigate the current standard of practice and
to determine the most beneficial and cost-effective method for reversing rocuronium, a
non-steroidal neuromuscular blocker. The reversal medications that were the focus of this
investigation were neostigmine and sugammadex. Neostigmine has been used in clinical
practice for many years to reverse the effects of rocuronium. Sugammadex is new to
clinical practice and specifically designed to reverse steroidal neuromuscular blockers
such as rocuronium. Analyzing the cost, patient benefits, and providers’ preferences were
the focus of this project.
Summary
In summary, the purpose of this project was to investigate whether sugammadex’s
benefits were worth the increased expense over neostigmine. Sugammadex and
neostigmine both reverse the effects of rocuronium, a neuromuscular blocker that causes
paralysis. A cost-benefit analysis was performed to determine which reversal technique
was superior and provided the most cost-effective care. A cost-analysis without the
2

considerations of benefits of each medication was considered but the investigation
revealed that more factors were involved in determining whether sugammadex or
neostigmine was the superior reversal technique.
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CHAPTER II – METHODOLOGY
Intervention
Once the project received approval from The University of Southern Mississippi
(USM), Institutional Review Board (IRB), and a north Mississippi delta hospital the cost
of each medication, surgical time, post-anesthesia care unit (PACU) time, and hospital
stay were documented for comparison. Using the obtained literature from the
investigation’s data search, a literature review was conducted to determine which
medication has the highest incidence of residual neuromuscular blockade and how this
affects discharge times from the PACU. The investigation calculated and compared each
medication to create a cost-benefit analysis to be presented to a north Mississippi delta
hospital. After completion, the detailed cost-benefit analysis was given to the chief
CRNA and anesthesiologist at the rural Mississippi hospital for review to increase
awareness and knowledge about the differences between the two reversal methods and
which option has better patient outcomes and is more cost-efficient.
DNP Essentials
The requirements for the doctoral nursing project (DNP) for the Commission on
Collegiate Nursing Education included meeting the American Association for Colleges of
Nursing (AACN) DNP Essentials (AACN, 2006). The cost-benefit analysis of
sugammadex versus neostigmine specifically meets all essentials as demonstrated in the
following:
•

Essential I, Scientific Underpinnings for Practice, was met by conducting a costbenefit analysis literature review of Neostigmine and Glycopyrrolate versus
Sugammadex, along with the costs, benefits, and risks of each. By integrating
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nursing science using analytics, the project was able to directly improve the
outcome of patient care.
•

Essential II, Organizational and Systems Leadership for Quality Improvement and
Systems Thinking, was met by determining which rocuronium reversal technique
is the most cost-effective in decreasing the costs for both patients and hospital
organizations.

•

Essential III, Clinical Scholarship and Analytical Methods for Evidence-based
practice were met by reviewing and utilizing a current literature review and
completing an itemized cost analysis for both neostigmine and glycopyrrolate
versus sugammadex.

•

Essential IV, Information Systems/Technology and Patient Care Technology for
the Improvement and Transformation of Health Care were met by utilizing the
organization’s Information Technology department in securing the necessary data
to allow for a thorough cost-benefit analysis to be completed.

•

Essential V, Health Care Policy for Advocacy in Health Care, was met because
the results of this project can help guide the organization in determining the most
cost-efficient and best practice standard when reversing the effects of rocuronium.

•

Essential VI, Inter-professional Collaboration for Improving Patient and
Population Health Outcomes were met by collaborating with a panel of anesthesia
professionals to help determine the cost savings and benefits of reversal
techniques for their patients and the organization.

•

Essential VII, Clinical Prevention and Population Health for Improving the
Nation’s Health was met because neuromuscular blocker reversals are essential in
5

anesthesia practice for reversing the effects of rocuronium, which is also essential
for recovery from anesthesia. By utilizing evidence to choose the most costefficient and safest technique of reversing rocuronium, patients will receive more
efficient and safer anesthetic care.
•

Essential VIII, Advanced Nursing Practice, was met by educating CRNAs and
anesthesiologists on the cost-benefit analysis results, then they will be encouraged
to utilize the provided evidence to implement the most cost-efficient and best
practice technique for reversing rocuronium.
Stakeholders
Stakeholders for this project included the Coordinator of the Nurse Anesthesia

Program, the chief CRNA of a small rural hospital in north Mississippi, and the
anesthesia staff, surgeons, PACU, and surgical patients at this small rural hospital.
Additional stakeholders included the nursing staff and the DNP project committee of this
project. One goal of this project was to provide stakeholders with the most evidencebased and cost-effective reversal technique when reversing rocuronium.
Data Collection and Analysis
The chief CRNA was approached at a rural hospital in north Mississippi about the
need for a cost-benefit analysis on neuromuscular blockade reversal. The lack of use of
the recently approved sugammadex, the first selective relaxant binding agent (SRBA) to
be introduced as a reversal for the clinical neuromuscular blockade was discussed in great
detail and how its high cost has deterred its use at the facility. One of the goals of this
project was to evaluate current care in small financially burdened hospitals and present
cost-effective alternatives that may help quality and reduce costs. The chief CRNA at this
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facility provided a detailed pharmacy report that included the cost of sugammadex,
neostigmine, and glycopyrrolate per vial as well as the operating room (OR) costs and
PACU costs. This information was used to develop a cost-benefit analysis for each
reversal technique.
The investigation utilized a thorough literature review to determine which
neuromuscular blockade reversal agent had less incidence of postoperative residual
paralysis. A cost-benefit analysis was then developed for the facility that included the
initial cost, cost over the intraoperative period, and the efficacy of each reversal method.
A voluntary questionnaire was offered to each CRNA working at the facility to determine
if there is a provider preference for which medication they use for neuromuscular
blockade. The data from the survey was then compiled, analyzed, and the results
summarized. The summarized survey results demonstrated the relevance of this
investigation and the potential impact it could have on anesthesia practice.
Measures
The desired goals of this project included determining the best practice for
reversing neuromuscular blockade and which medication was more cost-effective for the
provider. The investigation discovered which reversal method was more cost-effective
and provided improved patient outcomes by utilizing the information obtained from the
chief CRNA at a north Mississippi delta hospital and a thorough literature review for
neostigmine and sugammadex. The purpose of this investigation was to make a clear
determination for which medication was the best choice when considering medication
costs and benefits of neostigmine and sugammadex.
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Further, another vital role of this investigation was to help educate CRNAs and
other anesthesia providers about each reversal technique and provide evidence-based
literature as to whether sugammadex or neostigmine was superior. A panel of experts was
utilized to provide the investigation with their first- hand knowledge of their clinical
experience when administering neostigmine and sugammadex. Finally, the investigation
was able to make this determination after data was collected, with a completed literature
review, and detailed cost analysis.
Population and Setting
For this project, the population was surgical patients 18 years of age or older,
classified by the American Society of Anesthesiologist (ASA). The investigation chose
ASA I and II classifications who have received general anesthesia with a rocuroniuminduced neuromuscular blockade and were given either neostigmine and glycopyrrolate
or sugammadex for its reversal. Exclusion criteria included neuromuscular disorders,
diagnosed or suspected renal disease defined as an estimated creatinine clearance of <30
ml/min, hepatic dysfunction, allergies to sugammadex, neostigmine, glycopyrrolate, or
rocuronium, and planned admission to the hospital. The setting was a small, 220-bed
rural hospital in north Mississippi delta. The hospital performs approximately 6,000
surgeries a year.
Barriers
Barriers for this project included anesthesia providers' preferences for certain
medications used for neuromuscular blockade reversal. Inadequate train of four (TOF)
documentation by the anesthesia provider to determine the level of neuromuscular
blockade at the time of reversal could lead to the improper dosage of neuromuscular
8

reversal agents, altering the results of the overall research. The anesthesia provider
utilizes TOF monitoring to determine how paralyzed a patient is before selecting a
neuromuscular blockade reversal dose, this is vital because if an inadequate dose is
chosen then the patient is at risk for pulmonary aspiration and respiratory failure. Another
barrier is a lack of documentation of TOF in the PACU setting to determine if residual
neuromuscular blockade has occurred. Finally, the sample size of the population
surveyed was small due to facility size, a larger sample may have yielded different
results.
Ethical Considerations
The ethical considerations included two standards of care being delivered in the
intraoperative period for which cost-benefit analysis was conducted to find evidence
supporting the best neuromuscular blockade reversal. Further, CRNAs are responsible for
providing cost-effective anesthesia care at this rural facility The cost-benefit analysis has
been completed using evidence-based research, the CRNAs at this north Mississippi delta
hospital were given access to evidence-based knowledge needed to provide the best
standard of care by providing the safest and most cost-effective way to reverse
neuromuscular- blockade.
Discussion
Are the benefits of sugammadex worth the expense when reversing steroidal
neuromuscular blockers when compared to neostigmine and glycopyrrolate? Further, has
inexperience or possibly expense associated with sugammadex created a barrier to a
possible superior method when reversing steroidal neuromuscular blockers that would
greatly improve patient outcomes? Anesthesia providers have a great deal of
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independence, but with this independence comes increased responsibility that the
providers must be aware of, such as patient benefits and costs of certain anesthetic
techniques.
Utilizing paralytics is a common anesthetic practice that serves the purpose of
inducing neuromuscular blockade or paralysis during general anesthesia to paralyze the
vocal cords and jaw muscles to facilitate endotracheal intubation (Babu et al., 2018).
Neuromuscular blockade is a common practice in anesthesia, but neuromuscular blockers
have several risk factors that can lead to costly complications if not successfully reversed
postoperatively, for example, delayed discharge and post-operative ventilation requiring
critical care.
These complications can have a large impact on patient outcomes that ultimately
affect the financial reimbursement for quality care that is received. As the cost of health
care continues to rise and limited reimbursements from insurance companies,
organizations are continually trying to find ways to cut costs and increase profits. The
healthcare reform has forced anesthesia providers to critique their anesthetic plan to
ensure cost savings and make providers aware of anesthetic costs, such as medicines
(Zhou, 2016).
Complete neuromuscular strength is imperative in the recovery phase of
anesthesia to allow for appropriate ventilation and sensitivity to hypoxia to prevent
respiratory failure in the recovery room (Babu et al., 2018). The purpose of this project
was to investigate the costs and benefits of sugammadex versus neostigmine when used
for steroidal neuromuscular blockade reversal and whether or not it was preventing
improve patient outcomes. Neostigmine is the most commonly used anticholinesterase
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drug worldwide for neuromuscular blockade reversal (Zaouter et al., 2017). Neostigmine
is cost-effective but is usually co-administered with glycopyrrolate to counteract the
occurrence of its muscarinic side effects, such as nausea, vomiting, and bradycardia
(Insinga et al., 2016).
Sugammadex is a selective relaxant agent used as a reversal for clinical
neuromuscular blockade. “It is a modified gamma-cyclodextrin that works by
encapsulating and forming a very tight water-soluble complexes at a 1:1 ratio with
steroidal neuromuscular blocking drugs” (Nagelhout & Elisha, 2018, p.163).
Sugammadex was recently approved in the United States and has been shown to provide
a more consistent and faster reversal of rocuronium without the muscarinic side effects of
neostigmine (Insinga et al., 2016). The cost and benefits of each medication were the
focus of this investigation to determine the most evidence-based proven reversal method
and its associated cost.
Future implications of this study should closely follow the associated cost of
delayed discharge from the PACU and further investigate outpatient surgeries that had to
be admitted to the hospital due to post-operative residual paralysis due to inadequate
reversal with neostigmine. A thorough cost analysis needs to be conducted after this
event occurs to demonstrate the amount of funds that could be possibly lost due to not
meeting appropriate Centers for Medicare and Medicaid Services (CMS) guidelines. The
investigator could open the eyes of providers to look at more than just front-end purchase
cost of sugammadex and investigate the long-term cost and benefits of implementing
sugammadex into clinical practice.
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Summary
The expected outcome of this project was to determine which neuromuscular
blockade reversal agent would enhance OR efficiency and reduce complications related
to inadequate neuromuscular blockade reversal. The cost-benefit analysis was completed
by comparing the cost of each medication using the information obtained from the chief
CRNA. A literature review was then used to determine which reversal method had the
least amount of complications; the benefit analysis and the cost analysis were then
combined to create a cost-benefit analysis of neostigmine vs sugammadex.
The cost-benefit analysis was presented to a panel of experts, which included the
Nurse Anesthesia Program Coordinator, one USM College of Nursing and Health
Professions Associate Dean, and the current CRNA employed at the rural hospital. The
CRNAs at the small rural hospital were given a short questionnaire regarding their
current practice for neuromuscular blockade reversal. These results were carefully
analyzed and discussed as part of the investigation.
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CHAPTER III - Results
Analysis
Neostigmine is the most widely used reversal method for a neuromuscular
blockade; however, several life-threatening side effects are associated with its use such as
arrhythmias and bronchospasms. Neostigmine works on the parasympathetic system and
can cause severe bradycardia and must be administered with an anticholinergic to prevent
bradycardia. Neostigmine is also known for its slow onset of action and its inability to
reverse deep neuromuscular blockade. Sugammadex mechanism of action creates a faster
and safer reversal when compared to neostigmine. The most significant factor when
comparing neostigmine to sugammadex is its overwhelming ability to reverse deep
neuromuscular blockade reliably and quickly (Zaouter et al., 2017). Residual paralysis
occurs less frequently with sugammadex than neostigmine. “Residual paralysis may
increase morbidity by impairing coughing, swallowing, and the patient’s ability to
breathe deeply” (Ezri et al., 2016, p. 16).
In a 2015 study comparing sugammadex and neostigmine for reversing
neuromuscular blockade, sugammadex reduced all signs of residual postoperative
paralysis such as hypoxia, upper airway obstruction, and decreased oxygen saturation in
1553 participants (Abad-Gurumeta et al., 2015). Studies have consistently shown that
sugammadex reduces the clinical signs of postoperative residual paralysis caused by
rocuronium when compared to neostigmine. A study aimed to investigate residual
blockade and operating room discharge times, 154 adult patients undergoing abdominal
surgery were given rocuronium for neuromuscular blockade. None of 74 patients who
were given sugammadex for reversal showed signs of a residual blockade at PACU
13

admission, and 33 out of 76 patients who received neostigmine and glycopyrrolate had
symptoms of residual paralysis. Sugammadex also increased discharge times by 3.9
minutes respectively (Brueckmann et al., 2015).
A study involving 140 patients with a post-tetanic count of 1-2 received a dose of
4 milligrams per kilogram (mg/kg) dose of sugammadex, spontaneous recovery from
deep rocuronium-induced blockade occurred in 1.8-2.8 minutes compared to 50.4
minutes when using neostigmine. Deep neuromuscular blockade maintained until the end
of surgery shows to increase the quality of certain operational conditions, especially in
obese patients. Sugammadex is also associated with a shorter length of stay in PACU
because of faster recovery time and less pain (Zaouter et al., 2017).
Report of Findings
For this DNP project, data was obtained to develop a cost-benefit analysis of
neostigmine and glycopyrrolate vs sugammadex and implement a best practice
recommendation for the reversal of neuromuscular blockade in the intraoperative setting
by anesthesia providers. The student nurse anesthetists used evidence-based research that
was collected for comparison of each medication’s benefits. These benefits were
determined by two factors while performing the cost-benefit analysis. The first factor was
that multiple studies have shown that sugammadex provides faster recovery times when
compared to neostigmine, and the second factor was that the time saved can be converted
into shorter workdays or allow for more time to perform a greater number of surgeries
during the current work schedule. The cost of each medication was obtained from the
purchasing agent for the anesthesia department and then compared by adding the amount
used to reverse neuromuscular blockade (NMB) for a 100 kilogram patient as shown in
14

Table 1. The cost of OR and PACU time was also obtained from the purchasing agent for
the anesthesia department and documented in Table 2.
Table 1
Cost of Each Medication
Medication

Cost per vial

Sugammadex
Neostigmine
Glycopyrrolate

$70.72
$6.57
$1.84

Est. cost per surgical case
for a 100kg patient
$70.72
$6.57
$3.70

Table 2
Cost of Operating Room and PACU Time
Surgical Area

First 30 minutes

Operating Room
PACU

$1533
$1109

Every minute after 30
minutes
$29
$29

According to studies documented by Zaouter et al. (2017), sugammadex provides
favorable cost-effectiveness based on its ability to reduce the amount of time to reach a
TOF ratio of .9 in the OR after neuromuscular blockade reversal when compared to
neostigmine. Sugammadex has demonstrated its cost-effectiveness and when combined
with less post-operative complications when using sugammadex could provide the
facility cost savings and time to perform more surgeries. That time was then multiplied
by the cost of an OR time per minute to determine a per case cost saving. Time saved
when reversing NMB with sugammadex compared to neostigmine was documented in
Table 3.
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Table 3
Time Saved When Reversing NMB with Sugammadex Compared to Neostigmine
Depth of
blockade
Superficial
NMB
Moderate NMB
Deep NMB

Medication dose Time reduced
to reach a TOF
of 0.9
2 mg/kg
17 minutes

Amount saved
per surgical
case
$432.05

Amount
Saved Over
800 Cases
$345,640

2-4 mg/kg

18.6 minutes

4 mg/kg

47.5 minutes

$478.95 $408.23
$1,246.33

$326,584 $383,160
$997,064

Descriptive statistics were used from adult abdominal cases over a six-month
period at a hospital in the north delta of Mississippi to determine a cost-benefit analysis
(CBA) by comparing the cost per case of each reversal technique performed and then
using the obtained research to demonstrate the costs and benefits of sugammadex based
on the time saved from a faster recovery.
Clinical Scenario 1 for Superficial NMB
Over a 6-month time period, 800 abdominal surgeries (estimated number of
surgeries performed during this time period) are performed and NMB is reversed with
sugammadex, 17 minutes of operating room time could be saved for each case when
compared to using neostigmine. Implementation of sugammadex would create a cost
savings of $345,640 over this time period. These savings only increase with the depth of
NMB that is needed to be reversed. This cost savings could be as high as $997,064 over a
6-month period if the best practice guideline for the facility for NMB reversal was
sugammadex.
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Clinical Scenario 2 for Superficial NMB
The average time for an abdominal case is approximately 90 minutes, which
allows 5 abdominal surgeries to be performed in one room or by one surgeon in an 8-hour
day. If 17 minutes could be saved with a reversal of NMB with sugammadex, the time
saved with sugammadex would allow for an extra 85 minutes per day. An extra 85
minutes per day would allow time for an extra 109 cases over a 6-month period if
sugammadex is implemented into clinical practice at the north Mississippi delta hospital.
Implementation into Clinical Practice
Implementation of sugammadex use in reversing rocuronium in a north
Mississippi delta hospital could be accomplished easily and further increase cost savings
and improve patient outcomes for this hospital. Provider training will not have any
associated costs but may encounter some pushback from providers due to change in
technique in reversing rocuronium. Further, the providers already have access to
sugammadex and have used this medication in practice but do not utilize it consistently
due to cost. As mentioned earlier, the largest barrier to implementation of sugammadex
into clinical practice are providers becoming convinced that sugammadex over time will
increase savings and improve patient outcomes. Implementation of sugammadex into
clinical practice could simply be accomplished by replacing neostigmine and robinal with
sugammadex when reversing the paralytic effects of rocuronium.
Summary
In summary, the cost-benefit analysis of neostigmine versus sugammadex
demonstrated that the purchasing price of sugammadex was more expensive than the cost
of neostigmine, but after a thorough literature review and detailed cost analysis, the
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investigation found that sugammadex could potentially have a cost savings of $345,640
to $997,064 over a 6-month period, by increasing the rate of discharge from the operating
room. The potential cost savings would arise from the ability of sugammadex to rapidly
reverse the effects of rocuronium, unlike neostigmine, as well as protect the patient from
postoperative neuromuscular residual paralysis. Implementation of sugammadex into
clinical practice could be accomplished by providing the anesthesia department with the
cost-benefit analysis of sugammadex versus neostigmine demonstrating the benefits of
sugammadex outweigh its cost.
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CHAPTER IV – DISCUSSION
Correlation to Clinical Practice by Survey
The participants were chosen because they have significant clinical experience
with neostigmine and sugammadex and a combined 50 years of anesthesia experience.
Further, this panel of experts was practicing at the facility when the descriptive statistics
were obtained for cost comparison and have a particular interest in whether the North
Mississippi delta hospital should implement sugammadex to improve outcomes of their
patients and find potential cost savings. The survey consisted of seven questions that can
be viewed in Appendix c. This survey helped correlate real clinical practice to the
investigation.
Survey in Use of Sugammadex and Neostigmine
The panel of experts took a voluntary and unanimous survey to describe how their
facility utilizes sugammadex and neostigmine. The purpose of this survey was to discover
how relevant this investigation was to clinical anesthesia practice. This survey can be
found in Appendix C under the table of contents. The results of the survey found that 1
out of 7 providers preferred sugammadex over neostigmine, which the survey further
revealed that the other 6 providers preferred neostigmine due to the cost of sugammadex.
Further, all 7 providers answered that if sugammadex had the same cost as neostigmine
that they would implement the reversal method more in their clinical practice.
In regard to the clinical benefits of sugammadex versus its cost, 1 out of 7
providers answered that the benefits of sugammadex does not overcome its cost. All 7
participants have sugammadex and neostigmine readily available at their facility and
have the independence to decide which reversal method to choose. The results of this
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survey demonstrated the importance of this investigation and the results of the
investigation could have a direct impact on the anesthesia practice at this facility.
Limitations
The cost-benefit analysis of sugammadex versus neostigmine could possibly have
several limitations that could alter the results of this project. The first factor that could
impact this study is the size of the facility selected for this project, the north Mississippi
delta hospital is a 220-bed facility and findings may not adequately represent larger
facilities. Further, the investigation was based solely on abdominal procedures and did
not investigate other types of procedures where deep paralysis was warranted for surgery.
Approximately 800 abdominal surgical cases were performed where rocuronium was
used to induce muscle paralysis. This amount may not accurately reflect the possible cost
savings for facilities that perform more or less abdominal surgeries over a six-month
period. Further, the sample size of the population surveyed was small due to facility size,
a larger sample may have yielded different results. Finally, only 7 anesthesia providers
participated in the survey, which may not accurately reflect the opinion of all anesthesia
providers.
Future Implications
Future implications of this study should closely follow the associated cost of
delayed discharge from the PACU and further investigate outpatient surgeries that had to
be admitted to the hospital due to post-operative residual paralysis due to inadequate
reversal with neostigmine. A thorough cost analysis needs to be conducted after this
event occurs to demonstrate the amount of funds that could be possibly loss due to not
meeting appropriate Centers for Medicare and Medicaid Services or CMS guidelines. The
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investigator could open the eyes of providers to look at more than just front-end purchase
cost of sugammadex and investigate the long-term cost and benefits of implementing
sugammadex into clinical practice.
Discussion
The needs assessment conducted with the chief CRNA at this facility indicated
that cost was the main concern and reason for choosing neostigmine over sugammadex.
Further, providers at the chosen hospital also wanted to know whether the benefits of
sugammadex outweighed the cost of the medication. The investigation revealed that
sugammadex is a superior reversal agent for reversing the paralytic effects of rocuronium
and if implemented fully into clinical practice could create a cost-effective surgical care
model. Finally, the investigation only took into account the cost savings during the intraoperative period and did not investigate the potential cost-savings that may occur in the
post-operative period as well.
Summary
In summary, the cost-benefit analysis of neostigmine versus sugammadex
demonstrated that the purchasing price of sugammadex was more expensive than the cost
of neostigmine, but after a thorough literature review and detailed cost analysis, the
investigation found that sugammadex could potentially have a cost savings of $345,640
to $997,064 over a 6-month period, by increasing the rate of discharge from the operating
room. Sugammadex has a purchasing cost of $70.72. If this reversal technique was used
for each of the 800 abdominal surgical cases over the 6-month period, the overall
purchasing cost would be $48,640. Implementing sugammadex into clinical practice
could have a potential cost savings of $345,640 at the minimum over a 6-month period
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after the purchasing cost of sugammadex is considered and more importantly will
drastically improve patient outcomes by preventing residual muscle paralysis from
incomplete reversal of paralysis.
Further consideration needs to be taken to remember the investigation only
considered abdominal cases and did not include the many other procedures that utilize
paralytics at the facility, further cost savings could be found by including all procedures
that utilize neuromuscular blockade. An evidence-based literature review and a detailed
cost analysis indicated sugammadex is far superior in reversing the effects of rocuronium
and can allow operating rooms to save a tremendous amount of money by improving
operating room discharge times, which would offset the purchasing cost of sugammadex
and create an efficient surgical care model.
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APPENDIX A – DNP Essentials
Essential I

Essential II

Essential III

Essential IV

Essential V

Essential VI

Scientific Underpinnings for Conducting a cost-benefit
Practice
analysis literature review of
neostigmine and
glycopyrrolate versus
sugammadex, along with
the costs, benefits, and
risks of each. By
integrating nursing science
using analytics, we will be
able to directly improve the
outcome of patient care.
Organizational and Systems Determining which
Leadership for Quality
rocuronium reversal
Improvement and Systems
technique is more costThinking
effective in decreasing the
costs for both patients and
the hospital.
Clinical Scholarship and
Reviewing and utilizing a
Analytical Methods for
current literature review
Evidence-Based Practice
and completing an itemized
cost-benefit analysis of
both neostigmine and
glycopyrrolate versus
sugammadex.
Information
Utilizing the organization’s
Systems/Technology and
Information Technology
Patient Care Technology for (IT) department in securing
the Improvement of
the necessary data to allow
Transformation of Health
for a thorough cost-benefit
Care
analysis to be completed.
Health Care Policy for
The results of this project
Advocacy in Health Care
can help guide the
organization in determining
the most cost-efficient and
best practice standard when
reversing the effects of
rocuronium.
Inter-professional
Collaborating with a panel
Collaboration for Improving of anesthesia professionals
Patient and Population
to help determine the cost
Health Outcomes
savings and benefits of
paralytic reversal
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Essential VII

Clinical Prevention and
Population Health for
Improving the Nation’s
Health

Essential VIII

Advanced Nursing Practice
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techniques for their patients
and the organization.
Neuromuscular blocker
reversals are essential in
anesthesia practice for
reversing the effects of
rocuronium, which is also
essential for recovery from
anesthesia. By utilizing
evidence to choose the
most cost-efficient and
safest technique of
reversing rocuronium,
patients will receive more
efficient and safer
anesthetic care.
Educating CRNAs and
anesthesiologists on the
cost-benefit analysis
results, then they will be
encouraged to utilize the
provided evidence to
implement the most costefficient and best practice
technique for reversing
rocuronium.

APPENDIX B – IRB Approval Letter
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APPENDIX D – Project Summary
Purpose of Project
The purpose of this project was to investigate the current standard of practice and
to determine the most beneficial and cost-effective method for reversing rocuronium, a
non-steroidal neuromuscular blocker. The reversal medications that were the focus of this
investigation were neostigmine and sugammadex. Neostigmine has been used in clinical
practice for many years to reverse the effects of rocuronium. Sugammadex is new to
clinical practice and was specifically designed to reverse steroidal neuromuscular
blockers such as rocuronium. Analyzing the cost, patient benefits, and providers’
preferences were the focus of this investigation.
Report of Survey
The results of the survey found that 1 out of 7 providers preferred sugammadex
over neostigmine, which the survey further revealed that the other 6 providers preferred
neostigmine due to the cost of sugammadex. Further, all 7 providers answered that if
sugammadex had the same cost as neostigmine that they would implement the reversal
method more in their clinical practice. In regard to the clinical benefits of sugammadex
versus its cost, 1 out of 7 providers answered that the benefits of sugammadex does not
overcome its cost. All 7 participants have sugammadex and neostigmine readily available
at their facility and have the independence to decide which reversal method to choose.
The results of this survey demonstrated the importance of this investigation and the
results of the investigation could have a direct impact on the anesthesia practice at this
facility.
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Report of Main Findings of Each Medication
Neostigmine is the most widely used reversal method for a neuromuscular
blockade, however, there are several life-threatening side effects associated with its use
such as, arrhythmias and bronchospasms when the anticholinesterase outlast the vagolytic
action of the anticholinergic agents that is co-administered. Neostigmine is also known
for its slow onset of action and its inability to reverse deep neuromuscular blockade.
Sugammadex mechanism of action creates a faster and safer reversal when compared to
neostigmine. The most significant factor when comparing neostigmine to sugammadex is
its overwhelming ability to reverse deep neuromuscular blockade reliably and quickly
(Zaouter et al., 2017). Residual paralysis occurs less frequently with sugammadex than
neostigmine. “Residual paralysis may increase morbidity by impairing coughing,
swallowing, and the patient’s ability to breathe deeply” (Ezri et al., 2016, p.16).
Best Practice Recommendation
Through an evidence-based literature review and a detailed cost analysis,
sugammadex demonstrated it is far superior in reversing the effects of rocuronium and
can allow operating rooms to save a tremendous amount of money by improving
operating room discharge times, which would offset the purchasing cost of sugammadex
and create an efficient surgical care model.
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APPENDIX E – Survey of Sugammadex and Neostigmine Use

This is an anonymous survey in the use of Sugammadex and Neostigmine. Completion and
participation of this survey is voluntary.
Questionnaire:
1.

Which medication do you prefer when reversing neuromuscular blockade induced by
Rocuronium?
A. Sugammadex
B. Neostigmine and Glycopyrrolate

2. Does cost affect your decision when choosing a medication to reverse neuromuscular
blockade induced by Rocuronium?
A. Yes
B. No
3. Does your facility have a preference when reversing neuromuscular blockade induced by
Rocuronium?
A. No
B. Yes. If yes, list the medication.
4. Would you use Sugammadex more if the cost was the same as Neostigmine and
Glycopyrrolate?
A. Yes
B. No
5. Do you believe the benefits of Sugammadex can out way the cost?
A. Yes
B. No

6. Is sugammadex available at your facility?
A. Yes
B. No
7. Comments:
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APPENDIX F – Cost-Benefit Analysis of Sugammadex and Neostigmine
Cost-benefit analysis of sugammadex and neostigmine utilized an evidence-based
literature review and a detailed cost analysis, sugammadex demonstrated it is far superior
in reversing the effects of rocuronium and can allow operating rooms to save a
tremendous amount of money by improving operating room discharge times, which
would offset the purchasing cost of sugammadex and create an efficient surgical care
model. A cost analysis is listed below to demonstrate the cost differences of each reversal
technique.
Table A1.
Cost-Comparison of Sugammadex and Neostigmine and their Associated Cost
Medications
Actual Medication Cost
5 ml syringe
20-gauge needle
Co-Administered Drugs
Total:

Sugammadex
$70.72
$0.05
$0.02
$0
$70.79

Neostigmine
$6.57
$0.05
$0.02
$3.70
$10.34

Sugammadex had an administration cost of $70.79, while neostigmine had an
administration cost of $10.34. At first glance, an anesthesia provider would assume that
neostigmine was the less expensive option for reversing the effects of rocuronium, but the
provider must also take into account the long-term cost effects of each reversal method,
for example, the operating room time saved when using sugammadex instead of
neostigmine. The most significant factor when comparing neostigmine to sugammadex is
its overwhelming ability to reverse deep neuromuscular blockade reliably and quickly
(Zaouter et al., 2017).

31

Sugammadex has a purchasing cost of $70.72 if this reversal technique was used
over Neostigmine for each of the 800 abdominal surgical cases over the 6-month period
the overall purchasing cost of sugammadex would be $48,360 at the minimum. Further,
over a 6-month period after the purchasing cost of sugammadex is considered the
minimum cost savings would be $345,640 based on time saved during NMB reversal
over 800 abdominal surgical cases.
Table A2.
Time Saved when Reversing NMB with Sugammadex Compared to Neostigmine
Depth of
blockade
Superficial
NMB
Moderate NMB
Deep NMB

Medication dose Time reduced
to reach a TOF
of 0.9
2 mg/kg
17 minutes

Amount saved
per surgical
case
$432.05

Amount
Saved Over
800 Cases
$345,640

2-4 mg/kg

18.6 minutes

4 mg/kg

47.5 minutes

$478.95 $408.23
$1,246.33

$326,584 $383,160
$997,064

Benefits of sugammadex were demonstrated from the literature review, several
benefits were found including time saved during NMD reversal and decrease the
incidence of residual paralysis. If the average time for each abdominal case is 90 minutes,
this allows for 5 abdominal surgeries to be performed in one room or by one surgeon in
an 8-hour day. If 17 minutes could be saved with a reversal of NMB with sugammadex,
this could allow for an extra 85 minutes per day. That would allow time for an extra 109
cases over a 6-month period if Sugammadex is implemented into clinical practice at the
North Mississippi delta hospital. Residual paralysis occurs less frequently with
sugammadex than neostigmine. “Residual paralysis may increase morbidity by impairing
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coughing, swallowing, and the patient’s ability to breathe deeply” (Ezri et al., pg. 16,
2016).
In summary, the cost-benefit analysis of neostigmine versus sugammadex
demonstrated that the purchasing price of sugammadex was more expensive than the cost
of neostigmine, but after a thorough literature review and detailed cost analysis, the
investigation found that sugammadex could potentially have a cost savings of $345,640
to $997,064 over a 6-month period, by increasing the rate of discharge from the operating
room.
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APPENDIX G - Literature Matrix
Author

Research
type

Outcome
measures

AbadGurume
ta et al.,
2015.

A
systematic
review of
sugammad
ex vs
neostigmin
e for
reversal of
neuromusc
ular
blockade

Signs of
muscular
weakness and
drug-related
adverse events.

Babu et
al.,
2018.

Randomize
d control
study

This study was
to find out
whether
calcium
administration
after reversal
with
neostigmine
and
glycopyrrolate
could enhance
the recovery
from
neuromuscular
blockade.

Population
/Sample
size
1533
participants
from 17
randomized
studies.

60 patients
aged
between
18-60
belonging
to ASA 1
and 2.
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Pertinent
data from
results
Sugammadex
reduced all
signs of
residual
postoperative
paralysis and
minor
respiratory
events. There
was no
difference in
critical
respiratory
events.
Sugammadex
reduced drugrelated side
effects and
there was no
difference in
the rate of
postoperative
nausea and
vomiting.
Patients were
divided into
two groups
and reversed
with
neostigmine
.05mg/kg and
glycopyrrolate
.01mg/kg
followed by 10
ml of 10 %
calcium
gluconate in
the first group
and 10 ml of
normal saline
in the second
group. The
time of
attainment of
full muscle
power was
assessed by a
tongue
depressor test.

Suggested
Conclusions
This source
was useful in
the research
because it
provides data
about
postoperative
paralysis and
side effects
related to
each
medication.

Calcium
decreased the
response time
from an
average of
7.1 seconds
to 3.7
seconds after
the
administratio
n of
neostigmine
and
glycopyrrolat
e for NMB.

Brueck
mann et
al.,
2015.

Randomize
d control
studying
the effects
of
Sugammad
ex on the
postoperati
ve residual
neuromusc
ular
blockade.

The study was
aimed to
investigate
whether
reversal of
rocuroniuminduced NMB
with
Sugammadex
reduced the
incidence of the
residual
blockade and
facilitated OR
discharge
readiness.

154
randomized
patients.

Ezri et
al.,
2016.

Randomize
d study

Sugammadex
was compared
to neostigmine
in terms of
residual
paralysis
incidence in the
PACU.

150
patients
undergoing
abdominal
surgery.

Insinga
et al.,
2016.

Explorator
y analysis

Discrete event
simulation
model was
developed to
compare ORs
using
neostigmine
compared to

93
procedures
with
sugammad
ex and 91
with
neostigmin
e
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After
abdominal
surgery,
Sugammadex
reversal
eliminated
residual
neuromuscular
blockade in the
PACU and
shortened the
time from the
start of the
study
medication
administration
to the time the
patient was
ready for
discharge from
the operating
room.
No patient had
residual
paralysis after
reversal with
sugammadex
(0 out of 74)
compared to
43% after
neostigmine
(33 out of 76)
usual care
patients.
However, it
should be
emphasized
that residual
paralysis may
still occur after
reversal with
sugammadex
if a lower than
recommended
dose is
administered.
When using
sugammadex
compared to
neostigmine,
30 minutes of
OR time was
saved per
procedure.

Sugammadex
decreased
operating
room time by
3.9 minutes
when
compared to
neostigmine.

This source
will be useful
when
comparing
each method
of reversal for
residual
paralysis.

Sugammadex
can enhance
operating
room
efficiency
and
potentially
reduce the

sugammadex
for NMB
reversal and
how this
affected OR
procedure time
(Admission to
discharge).

Nagelho
ut &
Elisha,
2018.

Textbook

Zaouter
et al.,
2017.

Costeffective
analysis of
literature
from
January
2013October
2016

Properties of
medications and
their
mechanisms of
action.
Superficial,
moderate, and
deep NMB
reversal
meantime was
compared when
using
sugammadex
versus
neostigmine
and
glycopyrrolate.

N/A

PubMed
database
literature
over a fouryear
period.
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Paid overtime
hours dropped
from 84.1 to
32.0, with a
93% reduction
of a
postoperative
residual
blockade.
Residual NMB
was reduced
from 60% to
4% when
using
sugammadex
compared to
neostigmine
when full
neuromuscular
blockade
recovery was
not verified
before
extubating.
N/A

reduce
complications
of RNMB in
clinical
practice when
compared to
neostigmine.

Sugammadex
decreased OR
time during
superficial
NMB by 17
minutes,
moderate
NMB by 18.6
minutes and
deep NMB by
47.5 minutes
when
compared to
neostigmine.

Economic
impact relies
on faster
recovery
times and this
can be
converted to
positive
revenue for
the hospital.

N/A
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